Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

Monoclonal antibodies (mAbs) have revolutionized medicine, providing innovative treatments for many diseases. For decades, ...

Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...

If approved by the 10th June action date, clesrovimab could start competing with Sanofi and AstraZeneca's fast-growing Beyfortus (nirsevimab) – which got the go-ahead from the US regulator in ...

The green light in the US is the first worldwide for Enflonsia (clesrovimab) and makes the long-acting antibody the first competitor to Sanofi and AstraZeneca's blockbuster Beyfortus (nirsevimab ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody medicine. Nirsevimab provides protection with just one injection, ...